Saturday, March 09, 2024 10:22:39 PM
Hmm, pot calling the kettle black syndrome?
Nope. Madg claimed i was full of shit for claiming that Zimmer was a stakeholder in Sintx and that i was guaranteeing an acquisition. I addressed those claims and asked madg a question in return for which he has yet to respond to. In response to my response to Madg, Mictrade jumps into the conversation, changes the subject, and attacks my motives for simply showing evidence of why i claim Zimmer is a stakeholder in Sintx and why i believe that Zimmer will use Sintx for its strategic interests whether thats to acquire it or something more akin to what Eli did with Bristol Myers. Thus his post falls under disinformation because he's the one that changed the subject and did not in fact address any of the points i made to Madg in my replies to him. Incidently, you arent addressing my points either. Why are you claiming im the one who changed the subject when clearly MicTrade did?
How about you joe, will you answer my questions? Can Sintx and/or Zimmer include the testing data in the following two links in a submission to the FDA to receive clearance to commercialize a product together one day? Just to clarify, im not saying the data in this testing is enough for clearance. Im just asking could this testing data be part of a submission to the FDA of a product or products containing IP from both companies? If the answer is Yes, then Zimmer is a stakeholder.
https://ir.sintx.com/news-events/press-releases/detail/95/amedica-announces-results-of-independent-femoral-head-wear
https://www.sciencedirect.com/science/article/abs/pii/S1751616119309099
Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research.
Do you agree with my statement that Zimmer Biomet became a stakeholder the moment it allowed its IP to be tested with Sintx IP? It became an interested party in the test results. Thats what makes them a stakeholder!
I could, and have, argued that they have been a stakeholder since Sintx founding, (when you factor Centerpulse has been since Sintx began and Zimmer acquired Centerpulse) based on shared personnel, but the above is simple and more straightforward.
Joe, is the information below factual outside my belief that Eli Lilly and Bristol Myers made a deal behind the scenes and Icahn provided public cover for their deal? If you want you can comment on my opinion on behind the scenes deal. One last question if you wouldn't mind answering. Why is it when Sintx filed the IPO in 2007 it included the information that Zimmer purchased Centerpulse while Dr Link was CEO, but omitted that fact from the 2013 IPO?
You answer my questions ill answer yours...although im pretty sure i already answered this one previously.
========================================
Sintx - Zimmer connection in personnel is greater than this list. This list is to illustrate how Zimmer has had personnel leading Sintx since its founding connected to it and this means it can influence direction while protecting its interests.
Dr. Hofmann, MD -Co-Founder of Sintx (then Amedica) was a surgeon consultant for Centerpulse and then Zimmer
Dr. Link, PHD - Chariman of Sintx until 2014 was CEO of Centerpulse when Zimmer acquired it.
Dr. S Bal, MD - Chairman/CEO. Surgeon Consultant for Zimmer from 2002 to at least 2014.
https://www.sec.gov/Archives/edgar/data/1269026/000119312507120692/ds1.htm pg 73 &74
https://www.sec.gov/Archives/edgar/data/1269026/000119312513435409/d593074ds1.htm pg 89/90
========================================
Amylin - Eli connection via personnel
Howard E. Greene Jr - Sells Hybritech to Eli Lilly 1986. Founds Amylin 1987
Jospeh Cook - 28 year Eli Lilly Veteran joins 1994. Becomes Chairman/CEO 1998. Steps down as CEO in 2003. Removed as Chairman 2009 by Icahn
Ginger L. Graham - Exective at Eli Lilly until Lilly divests its medical device business in 1993 joins Cook on Amylin's board in 1994. Took over as CEO of Amylin when Cook stepped down in 2003.
Eli Lilly acquires ImClone 2008, partnered with Bristol Myers since 2002, with Carl Icahn aiding in purchase. Icahn then removes Cook as Chairman with Graham stepping down in 2009 before selling Amylin to Bristol Myers in 2012. In my opinion Eli Lilly and Bristol Myers did a trade of sorts behind the scenes both acquiring businesses each were partnered with and used Carl Icahn to provide the public cover for the behind the curtain deal.
https://www.latimes.com/archives/la-xpm-1986-03-19-fi-22814-story.html
https://www.twst.com/interview/joe-c-cook-jr-amylin-pharmaceuticals-amln
https://www.colorado.edu/biofrontiers/ginger-l-graham
Could it be that there is a strategy to distract people away from looking at the basic data?
Is all this an exercise to create more and more forum verbiage to drown out any serious discussion of evidence?
Recent SINT News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 01:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/10/2026 01:00:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:00:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 01:35:38 PM
- SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms • GlobeNewswire Inc. • 02/18/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/11/2026 01:45:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/11/2026 01:44:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/11/2026 01:43:48 AM
- SINTX Technologies to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on February 4–5 • GlobeNewswire Inc. • 01/29/2026 02:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/12/2025 05:15:20 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/09/2025 10:01:07 PM
- Sidoti Events, LLC's Year-End Virtual Investor Conference • ACCESS Newswire • 12/09/2025 05:48:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2025 01:00:05 PM
- SINTX Technologies to Participate in Sidoti & Company Investor Conference • GlobeNewswire Inc. • 12/08/2025 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2025 01:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2025 01:35:26 PM
- SINTX Technologies Signs Supply Agreement with EVONIK to Manufacture Silicon Nitride–PEEK Compound for AI-Assisted, 3D-Printed Patient-Specific Implants • GlobeNewswire Inc. • 12/01/2025 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 01:05:43 PM
- SINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational Efficiencies • GlobeNewswire Inc. • 11/13/2025 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 09:17:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/10/2025 01:00:06 PM
- SINTX Technologies Announces Launch of OsseoSculpt™ an Advanced Biologic for Use with SINAPTIC® Foot & Ankle Osteotomy Wedge System • GlobeNewswire Inc. • 11/03/2025 01:00:00 PM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
